GlassScriptPhysician profile
Waseem Ahmad
NPI 1124063375
$17,171.72
in general payments reported to CMS, 2019-2025
55 companies · $4,627 in 2025
The $4,627 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,430 · 2020: $1,227 · 2021: $2,118 · 2022: $1,644 · 2023: $2,323 · 2024: $3,802 · 2025: $4,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,392 · Travel and Lodging: $2,072 · Consulting Fee: $1,525 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,220 · Education: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,391.78 |
| Travel and Lodging | $2,072.35 |
| Consulting Fee | $1,525.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,220.00 |
| Education | $543.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,228.19 | 2023-2025 | |
| Globus Medical, INC. | $2,072.35 | 2024 | Excelsiusgps Robotic Navigation System |
| Teva Pharmaceuticals USA, INC. | $1,114.67 | 2019-2025 | Austedo Xr, Austedo |
| Livanova USA, INC. | $1,092.68 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Abbvie INC. | $973.01 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Harmony Biosciences LLC | $865.10 | 2020-2025 | Wakix |
| Novartis Pharmaceuticals Corporation | $698.36 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $614.95 | 2019-2025 | |
| Biogen, INC. | $528.80 | 2019-2024 | Avonex, Vumerity, Tysabri |
| Ucb, INC. | $445.76 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Lilly USA, LLC | $421.36 | 2019-2025 | Kisunla, Emgality, Reyvow |
| Lundbeck LLC | $418.29 | 2021-2025 | Vyepti, Rexulti |
| Genzyme Corporation | $379.88 | 2019-2022 | |
| Allergan, INC. | $343.85 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $299.10 | 2019-2025 | Ingrezza, Ongentys |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseem Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.